Aria Diagnostics (formerly known as Tandem Diagnostics), a San Jose, Calif.-based molecular diagnostics company, has secured more than $50m in Series C funding.
New investors Meritech Capital Partners and a prominent mutual fund group have joined existing investors Venrock and Domain Associates.
Led by John Stuelpnagel, DVM, and CEO Ken Song, MD, Aria Diagnostics is developing a directed approach to cell-free DNA (cfDNA) analysis in maternal blood to create a safe, highly accurate and affordable test for pregnant women.
The company intends to use the funding for product development and prepare commercialization of its proprietary prenatal test to detect common fetal trisomies such as Trisomy 21, which is associated with Down syndrome. Its laboratory facility in San Jose has received initial Clinical Laboratory Improvement Amendment (CLIA) certification.
FinSMEs
09/01/2012